WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

WAVE Life Sciences Ltd WVE-N531 Clinical Trial Update Call Transcript

Dec 19, 2022 / 01:30PM GMT
Release Date Price: €4.72 (-5.37%)
Operator

Good morning, and welcome to the Wave Life Sciences WVE-N531 proof-of-concept clinical trial conference call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, Investor Relations at Wave Life Sciences. Please go ahead.

Unidentified Company Representative

Thank you, operator. Good morning, and thank you for joining us today. I will be covering for Kate Rausch, while she's out on maternity leave. This morning, we issued a new release, providing an update on the initial cohort of our Phase Ib/IIa proof-of-concept clinical trial evaluating N531 as a potential treatment for Duchenne muscular dystrophy. A slide presentation to accompany this webcast is available at the Investor Relations section of our website at www.wavelifesciences.com. A replay will also be available on the website following today's call.

Before we begin, I would like to remind you that discussions during this conference call will include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot